Valuable Targets

What are CDKs inhibitors and how do you quickly get the latest development progress?

24 November 2023
4 min read

CDKs, or cyclin-dependent kinases, are a group of enzymes that play a crucial role in regulating the cell cycle in the human body. They work in conjunction with cyclins, which are proteins that activate CDKs at specific stages of the cell cycle. CDKs control the progression of the cell cycle by phosphorylating target proteins, thereby initiating various cellular processes such as DNA replication, cell division, and cell differentiation. Dysregulation of CDK activity has been implicated in numerous diseases, including cancer, making them attractive targets for drug development. Inhibitors of CDKs have shown promise in clinical trials as potential therapeutic agents for cancer treatment.

In recent years, research in the field of CDK inhibitors has primarily focused on furthering the selectivity of these inhibitors. In addition to CDK4/6 inhibitors, there are numerous candidate drugs for other subtypes (such as CDK1, CDK2, CDK7, CDK9, etc.) that have entered the clinical development stage which are noteworthy. CDK inhibitors have immense potential in the treatment of diseases such as diabetes, kidney diseases, neurodegenerative diseases, infectious diseases, and cancer. Four CDK inhibitors that target CDK4/6 have been introduced to the market globally. Trilaciclib has been approved for the treatment of bone marrow suppression, while Palbociclib, Ribociclib, and Abemaciclib are used to treat Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer. Many other CDK inhibitors also demonstrate potential in cancer treatment in clinical trials. This review discusses the relationship between CDK, cyclin, and cancer as well as the diversity of the coredom and molecular structure of broad-spectrum CDK inhibitors, aiming to serve as a reference for the development of new CDK inhibitors.

Based on the analysis of the provided data, Ocuphire Pharma, Inc. and Processa Pharmaceuticals, Inc. are leading in R&D progress with Phase 2 development for target CDKs. Indications such as solid tumors, breast cancer, and neoplasms have multiple drugs in development. Small molecule drugs are progressing rapidly, indicating their significance in the target CDKs space. The United States and China are the main countries driving development, with China showing some progress. Overall, the competitive landscape for target CDKs is dynamic, with potential for future advancements and approvals in various indications.

Potential Breakthrough in Cancer Treatment: The Power of CDKs Inhibitors

CDKs inhibitors are a type of drugs that target cyclin-dependent kinases (CDKs), which are enzymes involved in regulating the cell cycle. CDKs play a crucial role in cell division and proliferation. By inhibiting CDKs, these inhibitors can interfere with the cell cycle progression and potentially halt the growth of cancer cells.

From a biomedical perspective, CDKs inhibitors are primarily used in the field of oncology. They have shown promise as targeted therapies for various types of cancers, including breast cancer, lung cancer, and leukemia. By specifically targeting CDKs, these inhibitors can disrupt the uncontrolled cell growth and division that characterizes cancer.

CDKs inhibitors work by binding to the active site of CDKs, preventing them from phosphorylating their target proteins and thus disrupting the cell cycle. This interference can lead to cell cycle arrest and induce apoptosis (programmed cell death) in cancer cells.

It's worth noting that CDKs inhibitors are a diverse group of drugs, with different compounds targeting specific CDKs. Some examples of CDKs inhibitors include palbociclib, ribociclib, and abemaciclib, which are approved by the FDA for the treatment of certain types of breast cancer. These inhibitors are often used in combination with other therapies, such as hormone therapy, to enhance their effectiveness in treating cancer.

Catalog of CDKs Inhibitors

The currently marketed CDKs inhibitors include:

For more information, please click on the image below.

图形用户界面, 应用程序, Teams

描述已自动生成

What is the purpose of using CDKs inhibitors?

CDKs inhibitors are primarily used in the field of oncology. They have shown promise as targeted therapies for various types of cancers, including breast cancer, lung cancer, and leukemia. For more information, please click on the image below to log in and search.

图形用户界面

低可信度描述已自动生成

How to acquire the most recent advancement in CDKs inhibitors?

In the Synapse database, you can keep abreast of the latest research and development advances of CDKs inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

US approved Truqap (capivasertib) and Faslodex combo for advanced HR-positive breast cancer
Latest Hotspot
3 min read
US approved Truqap (capivasertib) and Faslodex combo for advanced HR-positive breast cancer
24 November 2023
US approval granted for combination of Truqap (capivasertib) and Faslodex for treating advanced HR-positive breast cancer patients.
Read →
An analysis of LY-3537982's R&D progress and its clinical results presented at the 2023 AACR Annual Meeting
An analysis of LY-3537982's R&D progress and its clinical results presented at the 2023 AACR Annual Meeting
24 November 2023
The initial results from LOXO-RAS-20001, a phase 1 study of LY3537982 in patients (pts) with KRAS G12C-mutant advanced solid tumors were reported at the AACR Congress.
Read →
Polaris Group begins phased BLA submission for ADI-PEG 20 to the U.S. FDA for Malignant Pleural Mesothelioma management
Latest Hotspot
3 min read
Polaris Group begins phased BLA submission for ADI-PEG 20 to the U.S. FDA for Malignant Pleural Mesothelioma management
24 November 2023
Polaris Group commences phased submission of a BLA for ADI-PEG 20 to the U.S. FDA to manage Malignant Pleural Mesothelioma.
Read →
What are ERK inhibitors and how do you quickly get the latest development progress?
What are ERK inhibitors and how do you quickly get the latest development progress?
24 November 2023
Inhibiting the downstream ERK can block cell signal transduction, and ERK inhibitors can overcome tumor cells' resistance to upstream target inhibitors. This gives them broader application prospects in clinical settings.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.